Nitrates Or Nitrites Or Nitric Acid Or Nitrogen Oxides Patents (Class 424/718)
-
Publication number: 20130266668Abstract: Methods which increase the bioavailability of beneficial gases in the circulatory system are provided. The methods involve administering agents that changes the binding affinity of a medicinal gas such as NO, CO, H2S, N2O, SO, SO2 and O2 for Hb and/or hemoglobin based oxygen carriers (HBOCs). The change results in increased release of gases carried by Hb and HBOCs. As a result, the concentration of the OH gases in circulation is raised, and they are more available to exert their beneficial effects, e.g. in the treatment of disease or conditions caused by low levels of the gases. The methods are optionally used together with administration of medicinal gases and/or administration of HBOCs and/or other non-HBOC gas carriers such as PFC, and as (or in conjunction with) diagnostic methods.Type: ApplicationFiled: December 1, 2011Publication date: October 10, 2013Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Martin Safo, Kevin R. Ward
-
Patent number: 8551536Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: GrantFiled: August 29, 2008Date of Patent: October 8, 2013Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Alabama at Birmingham, Wake Forest UniversityInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Publication number: 20130251823Abstract: An angiogenesis regulating composition used to treat/prevent an angiogenic disease in a subject, that contains in an effective amount at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, and an angiogenesis regulation method administering to a subject a composition containing as an active ingredient at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, provide a composition effective in treating and preventing angiogenic diseases, that can medically control angiogenic diseases, and medically regulate angiogenesis in ophthalmologic diseases in particular, and allows treatment without inhibiting physiological neovascularization, with a limited side effect and significantly safely, and an angiogenesis regulation method using the same.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Inventors: Junya FUJIMORI, Hidekazu Baba, Toshinori Murata
-
Publication number: 20130230606Abstract: The present disclosure relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, including: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The disclosure also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Applicant: NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Nicolas L. G. BARRAUD, Jeremy S. WEBB, Scott A. RICE, Staffan KJELLEBERG
-
Publication number: 20130224118Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: HEART METABOLICS LIMITEDInventor: Heart Metabolics Limited
-
Patent number: 8518457Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.Type: GrantFiled: November 10, 2006Date of Patent: August 27, 2013Assignee: Pulmonox Technologies CorporationInventors: Christopher C. Miller, Douglas R. Hole, Bruce R Murray, Bryan Perry
-
Publication number: 20130209584Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).Type: ApplicationFiled: February 20, 2013Publication date: August 15, 2013Applicant: TheraVasc Inc.Inventor: TheraVasc Inc.
-
Publication number: 20130202721Abstract: A system is disclosed that extracts bodily fluid to a reaction chamber for monitoring a substance or property of the patient fluid. In one embodiment, a pump is used to advance the sample of bodily fluid through a filter to produce a filtrate. Another pump advances filtrate into the reaction chamber, while another pump advances reactant into the reaction chamber. A sensor in communication with the reaction chamber determines a concentration of nitric oxide or one of its metabolic products. Methods are also disclosed.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Inventor: James H. Silver
-
Publication number: 20130195926Abstract: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.Type: ApplicationFiled: December 4, 2012Publication date: August 1, 2013Applicant: The General Hospital CorporationInventor: The General Hospital Corporation
-
Patent number: 8486451Abstract: Disclosed are metal organic frameworks that adsorb nitric oxide, NO-loaded metal organic frameworks, methods of preparing the NO-loaded metal organic frameworks, methods of releasing the nitric oxide into a solution or into air, and uses of the metal organic frameworks.Type: GrantFiled: August 16, 2007Date of Patent: July 16, 2013Assignee: The University Court of the University of St. AndrewsInventors: Russell Edward Morris, Paul Stewart Wheatley
-
Publication number: 20130171228Abstract: The present invention relates to metal organic framework materials which possess anti-microbial properties. The present invention also provides methods of preparing such metal organic framework materials and uses of the metal organic framework materials to prevent or treat microbial infections, or provide surfaces which limit contamination by micro-organisms.Type: ApplicationFiled: August 8, 2011Publication date: July 4, 2013Applicant: University Court of the University of St. AndrewsInventor: Russell Edward Morris
-
Publication number: 20130171272Abstract: The present invention relates to a method for generating nitric oxide, in particular for therapeutic applications, which comprises the steps of: guiding a process gas into a reaction chamber (12), wherein the process gas comprises nitrous oxide in a carrier gas in a concentration in the range of ?2 vol-%, in particular in the range of ?10-3 vol-% to ?1 vol-%, and heating the process gas to a temperature which is sufficiently high to enable a reaction of nitrous oxide to form nitric oxide, thereby forming a gas which at least partly comprises nitric oxide. This method allows generating nitric oxide without remarkable concentrations of toxic nitrogen oxides, in particular of nitrogen dioxide. The method according to the invention is particularly suitable for therapeutic applications.Type: ApplicationFiled: September 12, 2011Publication date: July 4, 2013Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Achim Gerhard Rolf Koerber, Rainer Hilbig
-
Publication number: 20130149282Abstract: The disclosure relates to edible and biodegradable eating utensils and edible and biodegradable containers. In one aspect a method of making and preserving an edible and biodegradable utensil or container is disclosed.Type: ApplicationFiled: December 10, 2012Publication date: June 13, 2013Inventor: David Christopher Marshall
-
Patent number: 8435570Abstract: Compositions comprising a nitrite salt, a nitrate salt, and ascorbic acid are provided in several embodiments. A method of enhancing cardiovascular performance or treating adverse cardiovascular event in a mammal is also provided.Type: GrantFiled: July 11, 2012Date of Patent: May 7, 2013Assignee: Board of Regents, The University of Texas SystemInventor: Nathan S. Bryan
-
Patent number: 8434475Abstract: A reaction and distribution system may include a distributor securable near or in a path correspond to a breathing passage such as the nostrils or the mouth of a user for delivering nitric oxide therapy thereto. The distributor may contain an internal reactor for creating the nitric oxide from reactants. Alternative embodiments may rely on a line delivering nitric oxide to the distributor from a remote generator such as a cannister carried in a pocket or placed/at the bedside of a user.Type: GrantFiled: January 28, 2009Date of Patent: May 7, 2013Assignee: Genosys, Inc.Inventors: Randy J. Miller, Christie M. Jones
-
Patent number: 8435569Abstract: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia.Type: GrantFiled: April 30, 2008Date of Patent: May 7, 2013Assignee: NNOXE Pharmaceutiques Inc.Inventor: Jacques H. Abraini
-
Publication number: 20130108715Abstract: Treatment for alleviating ischemia-reperfusion injury which has minimized risk of side effects and which can suppress neutrophilic infiltration and activation of platelets during ischemia reperfusion comprises administration by inhalation of a mixed gas comprising 21%-98% oxygen, 0.1%-4% hydrogen, 40-80 ppm nitrogen monoxide, and a remainder of inert gas such as nitrogen or helium to a patient undergoing reperfusion from immediately before the start of ischemia reperfusion until shortly after the start of reperfusion.Type: ApplicationFiled: March 2, 2011Publication date: May 2, 2013Applicant: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventors: Hirosuke Kobayashi, Toshihiro Shimbo, Kenichi Kokubo
-
Publication number: 20130108610Abstract: The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.Type: ApplicationFiled: October 28, 2011Publication date: May 2, 2013Inventors: James Robert SCHWARTZ, Charles Winston Saunders, Robert Scott Youngquist, Jun Xu
-
Patent number: 8431163Abstract: Disclosed are methods of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of nitric oxide gas.Type: GrantFiled: October 15, 2012Date of Patent: April 30, 2013Assignee: INO Therapeutics LLCInventors: James S. Baldassarre, Ralf Rosskamp
-
Patent number: 8425945Abstract: The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The invention also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant.Type: GrantFiled: May 24, 2006Date of Patent: April 23, 2013Assignee: NewSouth Innovations Pty LimitedInventors: Nicolas Louis Gabriel Barraud, Jeremy Stephen Webb, Scott Alan Rice
-
Publication number: 20130095194Abstract: The invention relates to a gaseous inhalable medicament containing xenon or N2O as active ingredient for use by inhalation for preventing and/or for treating neuropathic pain or pains caused by at least one cancer chemotherapy substance administered to a patient suffering from cancer, in particular a patient suffering from breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, rectal cancer or a gastric cancer or cancer of the upper aerodigestive tracts. The cancer chemotherapy substance contains one or more compounds chosen from platinum salts, taxanes, alkaloids, thalidomide and bortezomib, in particular paclitaxel, docetaxel or oxaliplatin. The effective volume proportion of nitrous oxide or of xenon is between 5 and 70%.Type: ApplicationFiled: October 9, 2012Publication date: April 18, 2013Applicant: L'Air Liquide, Société Anonyme pour I'Etude et I'Exploitation des Procédés Georges ClaudeInventor: L'Air Liquide, Société Anonyme pour I'Etude et
-
Publication number: 20130089629Abstract: A kit for the treatment of onychomycosis by nitric oxide, including: a) a pre-treatment part comprising a pharmaceutically acceptable acidifying agent in an amount sufficient to loosen up the superficial outer nail plate layer, b) a treatment part comprising a pharmaceutically acceptable nitrite and at least one polysaccharide or a NO eluting polymer in one container and ascorbic acid in another container in amounts sufficient to produce nitric oxide in an amount that reduces and/or eliminates the onychomycosis upon being mixed and c) at least two devices suitable to apply a) and b) at the treatment site and upon treatment secure that the treatment site is substantially sealed.Type: ApplicationFiled: June 7, 2011Publication date: April 11, 2013Applicant: TOPICAL PHARMA ABInventors: Goeran Beijer, Joergen Midander
-
Publication number: 20130084336Abstract: Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions.Type: ApplicationFiled: June 26, 2012Publication date: April 4, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Adam Friedman, Joel Friedman, Joshua Nosanchuk, Parimala Nacharaju, Karin Blecher, Chaim Tuckman-Vernon
-
Patent number: 8410175Abstract: An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply.Type: GrantFiled: December 22, 2008Date of Patent: April 2, 2013Assignee: Nippon Kayaku Kabushiki KaishaInventors: Hiroyasu Yasuda, Mutsuo Yamaya, Katsutoshi Nakayama, Hidetada Sasaki
-
Publication number: 20130078321Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.Type: ApplicationFiled: November 21, 2012Publication date: March 28, 2013Applicant: INO Therapeutics LLCInventor: INO Therapeutics LLC
-
Publication number: 20130078298Abstract: A process of preparing articles having gaseous NO sequestered therein is disclosed, as well as articles prepared thereby. Also disclosed are articles having gaseous NO sequestered therewithin and having reduced amount of oxygen-containing and/or nitrogen-containing reactive species. Also disclosed are processes of preparing packaged articles having a non-gas permeable package that comprises gaseous NO therein and packaged articles made therefrom. Also disclosed are charging devices which can be utilized in the above-described processes. The articles prepared by the above-described processes are preferably medical devices such as indwelling catheters, intubation devices and tampons. Tampons having sequestered therein gaseous NO, uses thereof and processes of preparing same are also disclosed.Type: ApplicationFiled: May 9, 2011Publication date: March 28, 2013Applicant: Enox Biopharma, IncInventors: Yossef Av-Gay, Christopher C. Miller, Deborah Bohbot, Gilly Regev-Shoshani
-
Publication number: 20130071371Abstract: A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicants: NEOGENIS LABS, INC., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Nathan S. Bryan, Jose G. Rocca
-
Publication number: 20130071494Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.Type: ApplicationFiled: November 5, 2012Publication date: March 21, 2013Inventors: Nathan S. Bryan, Janet Zand
-
Patent number: 8399005Abstract: The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced.Type: GrantFiled: October 10, 2008Date of Patent: March 19, 2013Assignee: University of North Carolina at Chapel HillInventors: Mark H. Schoenfisch, Evan M. Hetrick, Nathan A. Stasko, C. Bryce Johnson
-
Publication number: 20130059017Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.Type: ApplicationFiled: March 17, 2012Publication date: March 7, 2013Applicant: Transdermal Biotechinology, Inc.Inventors: Nicholas V. Perricone, Yousry Abdelrehim Sayed
-
Publication number: 20130039995Abstract: Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.Type: ApplicationFiled: October 12, 2012Publication date: February 14, 2013Applicant: Galderma Research & DevelopmentInventor: Galderma Research & Development
-
Publication number: 20130040000Abstract: Disclosed are methods of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of nitric oxide gas.Type: ApplicationFiled: October 15, 2012Publication date: February 14, 2013Applicant: INO THERAPEUTICS LLCInventor: INO THERAPEUTICS LLC
-
Publication number: 20130028942Abstract: Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.Type: ApplicationFiled: September 25, 2012Publication date: January 31, 2013Applicant: AIRES PHARMACEUTICALS, INC.Inventor: AIRES PHARMACEUTICALS, INC.
-
Publication number: 20130022691Abstract: An apparatus for controlled delivery of nitric oxide. A pump draws air through an activated carbon filter and into a reaction chamber. The generation of nitric oxide occurs in the reaction chamber. A second pump draws the gas in the reaction chamber through a calcium hydroxide filter and delivers the nitric oxide through an orifice, or aperture, that controls the flow of nitric oxide delivered. The nitric oxide is filtered through a calcium hydroxide filter just prior to being made available for various nitric oxide therapies. Topical applications that provide a nitric oxide therapy to a surface are also provided.Type: ApplicationFiled: August 3, 2011Publication date: January 24, 2013Inventors: J.W. Randolph Miller, John J. Miller, Stephen H. Fairbanks
-
Publication number: 20130017174Abstract: Probiotic compositions comprising a bacterium that is capable of producing nitric oxide and a substrate of nitric oxide synthase are provided. Also provided are methods of improving the gastrointestinal health of a subject by orally administering a bacterium capable of producing nitric oxide and orally administering a substrate of nitric oxide synthase. Methods of reducing the inflammatory immune response after treatment with a probiotic and methods of reducing horizontal transmission of pathogenic bacteria within groups of animals are also provided.Type: ApplicationFiled: July 12, 2012Publication date: January 17, 2013Applicant: The Board of Trustees of the University of ArkansasInventors: Billy Hargis, Neil Pumford, Amanda Wolfenden
-
Publication number: 20130017277Abstract: Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.Type: ApplicationFiled: July 23, 2012Publication date: January 17, 2013Inventors: David R. Rounbehler, David H. Fine
-
Publication number: 20120330224Abstract: A compound for the manufacturing of a medicament for reducing or preventing mesothelial cell damage includes a mixture of a carrier gas and between 1 volume percent and 29 volume percent of nitrous oxide gas (N2O) and can be used for prevention of adhesion formation, pain reduction, reducing or preventing acute inflammation, reducing or preventing CO2 resorbtion or reducing tumor cell implantation upon surgery.Type: ApplicationFiled: March 7, 2011Publication date: December 27, 2012Inventors: Karina Mailova, Leila Adamyan
-
Publication number: 20120321724Abstract: A method of measuring in vivo nitric oxide and nitrite levels in individuals by providing a salivary nitrite test substrate, testing salivary nitrite levels with the test substrate, measuring nitrite levels detected in the testing; and correlating the measured nitrite levels with in vivo nitric oxide bio-availability.Type: ApplicationFiled: August 13, 2012Publication date: December 20, 2012Inventor: Nathan S. Bryan
-
Publication number: 20120323310Abstract: The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.Type: ApplicationFiled: January 24, 2012Publication date: December 20, 2012Applicant: CELONOVA BIOSCIENCES, INC.Inventors: James W. Larrick, James C. Peacock, III
-
Publication number: 20120318262Abstract: The present invention concerns a pyrvinium compound or salt or an analog thereof for the treatment of wounds. The present invention also concerns devices for delivering a pyrvinium compound or salt or an analog thereof for a wound.Type: ApplicationFiled: March 21, 2012Publication date: December 20, 2012Inventors: Ethan Lee, Pampee Paul Young
-
Patent number: 8333997Abstract: The invention provides compositions for releasing nitric oxide (NO) comprising a matrix that encapsulates nitric oxide. Nitric oxide is released when the composition is exposed to an aqueous environment. The invention further provides methods of preparing the compositions and uses of the compositions for treating infections and disorders.Type: GrantFiled: June 20, 2007Date of Patent: December 18, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Joel M. Friedman, Adam Friedman, Mahantesh S. Navati
-
Publication number: 20120309623Abstract: Provided in various embodiments are surface-modified hydrogels and hydrogel microparticles, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, and agricultural active ingredients. In some embodiments, such hydrogels and hydrogel microparticles comprise surface coatings that are resistant to solvent washing and can act as barriers for the migration of water and/or water-compatible alcohols and actives soluble therein.Type: ApplicationFiled: February 17, 2011Publication date: December 6, 2012Inventors: Dongchan Ahn, James Thompson
-
Publication number: 20120288488Abstract: Compositions and methods for preventing or controlling bacteria, viruses and parasitic growths that cause diarrhea, pneumonia and septicemia in animals comprising a biocidal system comprised of a primary biocide and a pH buffer component; a cationic or ionic surfactant having an HLB of from about 5 to about 30; a thickening agent; and an aqueous based carrier.Type: ApplicationFiled: January 9, 2012Publication date: November 15, 2012Applicant: NOBLE ION, LLCInventors: Burt R. Sookram, John W. Veenstra
-
Patent number: 8303995Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Methods of reducing triglycerides or reducing C-reactive protein levels are also provided.Type: GrantFiled: August 16, 2010Date of Patent: November 6, 2012Assignees: Board of Regents, The University of Texas System, Neogenis Laboratories, Inc.Inventors: Nathan Scott Bryan, Janet Zand
-
Publication number: 20120276152Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.Type: ApplicationFiled: February 6, 2012Publication date: November 1, 2012Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
-
Patent number: 8298589Abstract: Compositions comprising a nitrite salt, a nitrate salt, and ascorbic acid are provided in several embodiments. Use of said composition in a method of enhancing cardiovascular performance or treating adverse cardiovascular event in a mammal is also provided.Type: GrantFiled: June 15, 2009Date of Patent: October 30, 2012Assignee: Board of Regents, The University of Texas SystemInventor: Nathan Scott Bryan
-
Patent number: 8293284Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.Type: GrantFiled: June 22, 2010Date of Patent: October 23, 2012Assignee: INO Therapeutics LLCInventors: James S. Baldassarre, Ralf Rosskamp
-
Patent number: 8282967Abstract: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.Type: GrantFiled: June 24, 2011Date of Patent: October 9, 2012Assignee: The University of North Carolina at Chapel HillInventors: Mark H. Schoenfisch, Jae Ho Shin, Nathan Stasko
-
Patent number: 8282966Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.Type: GrantFiled: June 22, 2010Date of Patent: October 9, 2012Assignee: INO Therapeutics LLCInventors: James S. Baldassarre, Ralf Rosskamp
-
Patent number: 8277829Abstract: A biocompatible inorganic porous material having a three-dimensional coexistent network of interconnected macro-pores and nanopores produced by the steps of mixing an organic water-soluble polymer (e.g., polyethylene oxide or a block copolymer of ethylene oxide and propylene oxide), an alkoxysilane, and an inorganic water-soluble calcium salt in an aqueous acid solution, such that a sol-gel process of hydrolysis and polycondensation is initiated and thereby producing a gel; drying the gel to remove solvent by evaporation; and heating the gel to remove the polymer by thermal decomposition, thereby forming an inorganic porous material, which may be suitable for use as a bone tissue scaffold.Type: GrantFiled: August 30, 2007Date of Patent: October 2, 2012Assignee: Lehigh UniversityInventors: Himanshu Jain, Ana C. Marques, Rui M. Almeida